Destiny Pharma plc

(“Destiny Pharma” or “the Company”)

Further information re AGM

Brighton, United Kingdom – 25 May 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, as announced on 19 May 2021, will operate a virtual facility to allow Shareholders to listen in to the business of its Annual General Meeting (“AGM”) to be held at 11.00am BST on 3 June 2021.

The Company is using the Investor Meet Company platform. This platform will allow Shareholders to follow proceedings of the AGM and hear from the Company via the live presentation and Q&A session immediately following the AGM. The Company will also
provide an online recording, available on the Investor Meet Company platform and the Company’s website after the meeting.

Shareholders who wish to attend the online presentation should register for the event in advance via the following link:
https://www.investormeetcompany.com/destiny-pharma-plc/register-investor.

Shareholders are invited to pre-submit questions either to agm2021@destinypharma.com or online via the Investor Meet Company dashboard up until 17.00pm BST on 2 June 2021 or during the meeting itself via the Q&A function. Please include the Shareholder’s name and Shareholder Reference Number (which can be found on the share certificate or proxy form).
Shareholders wishing to vote at the AGM are strongly encouraged to do so by completing a form of proxy, appointing the Chairman of the AGM as their proxy. Shareholders will not be able to vote at the AGM over the online platform.

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 127 370 4440
pressoffice@destinypharma.com

Optimum Strategic Communications
Mary Clark/ Shabnam Bashir/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com

finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 207 220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a
novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information on the company, please visit https://www.destinypharma.com

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Notice to Register for 2021 AGM

Brighton, United Kingdom – 19 May 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, as announced on 4 May 2021, will hold its 2021 Annual General Meeting (“AGM”) at the offices of finnCap Ltd, Destiny Pharma’s Nominated Advisor and Joint Broker, at 11.00am BST on 3 June 2021. Destiny Pharma will operate an audio dial-in facility to allow Shareholders to listen to the business of the meeting.

As previously announced in the Posting of Annual Report and Notice of AGM, whilst in normal circumstances the Board values the opportunity to engage with shareholders in person at its AGM, on this occasion the Board feels it is appropriate to advise shareholders against travelling to attend the AGM in person and, instead, to submit proxy votes as early as possible because, as matters currently stand, shareholders will not be granted access to the AGM. Shareholders are strongly advised to appoint the Chairman of the AGM as their proxy.

Immediately following the AGM at 11:00am BST, Destiny Pharma will host a live webcast presentation followed by Q&A.

Shareholders will not get an opportunity to vote or ask questions or any other participation during the call but are encouraged to pre-submit any questions for Directors of the Company in advance of the AGM to agm2021@destinypharma.com by no later than 17:00pm BST on 2 June, 2021. Please include the Shareholder’s name and Shareholder Reference Number (which can be found on the share certificate or proxy form) in your email.

A full recording of the 2021 AGM will be made available on the Company’s website at www.destinypharma.com 

For further information, please contact: 

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com 

Optimum Strategic Communications
Mary Clark, Shabnam Bashir, Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com 

finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects. 

For further information on the company, please visit  https://www.destinypharma.com

Destiny Pharma plc
(“Destiny Pharma” or the “Company”)

Destiny Pharma Conference Attendance for May 2021

Brighton, United Kingdom – 6^th May 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that its management team will be presenting and participating at the following conferences:

Proactive One2One Virtual Forum – Thursday 6^th May 2021 at 7:00pm BST

Neil Clark, CEO will present at this virtual event, hosted by Proactive Investors. 

Destiny Pharma has been invited to present as a ‘Leading Growth Company’ to provide an overview of the Company and its innovative pipeline.

BioEquity Europe – Tuesday 18^th May 2021

William Love, Founder and CSO will present and participate in “What is the Next Act for Antibiotics?” panel discussion.

The distinguished panel entitled “What is the Next Act for Antibiotics” includes investors and antibiotics leaders, such as Destiny Pharma, who will discuss and identify the requirements for new mechanisms to incentivize the next act of antibiotics investment and development. The Panel, chaired by Steve Usdin, Senior Editor & Head Policy and Regulation, BioCentury, includes:

• Frank Kalkbrenner, Ph.D., Global Head, Boehringer Ingelheim Venture Fund
• William Love, Ph.D., Founder & CSO, Destiny Pharma
• John Rex, Ph.D., Chief Medical Officer & Director, F2G Ltd. and Editor in Chief, AMR Solutions
• Henry Skinner, Ph.D., CEO, AMR Action Fund
• Rafaèle Tordjman, Founder & CEO, Jeito Capital

In addition to the panel discussion, Destiny Pharma will also be presenting to potential partners and investors in attendance.

If you would like to virtually meet with Destiny Pharma, please email us on conferences@destinypharma.com

Enquiries:

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infections in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information on the Company, please visit www.destinypharma.com